Stakeholders in the retinal vein occlusion market are under scrutiny to provide efficient care and support to patients during the ongoing COVID-19 pandemic. Pharmaceutical companies are boosting their production capabilities to ensure the robust supply of drugs and therapeutics in hospitals, clinics, and emergency settings. As such, the pandemic has compelled patients to delay or cancel their treatment, which is affecting the sales of therapeutics. Nevertheless, telehealth services and mobile apps are helping to revive the growth of the retinal vein occlusion market.
An increasing number of individuals are opting for remote health services. This has led to the demand for telehealth services and mobile apps during the ongoing pandemic. Mass vaccination programs are anticipated to boost the revenue flow in the global economy.
To know the scope of our report Get a Sample on Retinal Vein Occlusion Market
The retinal vein occlusion market is expected to surpass US$ 32.5 Bn by 2031. However, there is a need for full ophthalmologic examination when retinal vein occlusion (RVO) is suspected, along with a VA (Visual Acuity) measurement in order to improve patient outcomes. There is increased awareness about iris examination to rule out neovascularization.
In order to improve clinical numbers, healthcare providers are taking into consideration the medical history and paying attention to examinations carried out for achieving efficient diagnosis of RVO. The presence of macular edema (ME) and the extent of retinal ischemia are being evaluated. Healthcare companies are gaining awareness that long-term monitoring of patients should be individualized to combine maintenance with practicability. While steroids may be considered in patients with systemic cardiovascular risk, surgery is advisable only for few and specific patient cases.
Get a glimpse of the in-depth analysis through our Report Brochure
Retinal vein occlusion is the second-most common retinal vascular disease, which can potentially lead to loss of vision. Since ranibizumab is approved by the U.S. Food and Drug Administration (USFDA) for the treatment of ME secondary to RVO. This is benefitting stakeholders in the India retinal vein occlusion market since the Drug Controller General of India (DCGI) has also approved ranibizumab for the treatment of macular edema caused by retinal vein occlusion.
Large, randomized, and controlled clinical trials are substantiating the efficacy of anti-VEGF (vascular endothelial cell growth factor) agents, including ranibizumab for the treatment of ME secondary to RVO. Such findings are translating into revenue opportunities for companies in the retinal vein occlusion market. Ranibizumab for the treatment of ME caused by branch retinal vein occlusion (BRVO) showed rapid and sustained visual improvement in patients who received monthly intravitreal injections of the drug.
The high prevalence of cardiovascular and other systemic diseases in Nepal is contributing to the growth of the Nepal retinal vein occlusion market. Treatment options such as laser photocoagulation and intravitreal injections of either VEGF inhibitors or steroids are being publicized. It has been found that intravitreal injections of VEGF inhibitors for RVO result in good visual and anatomic outcomes as compared to macular laser photocoagulation or intravitreal injections of triamcinolone.
Companies in the retinal vein occlusion market are increasing their production capabilities in VEGF inhibitors that are gaining popularity as the preferred first line agents in the treatment of RVO. It has been found that the choice of VEGF inhibitors among countries varies as per their drug regulatory processes.
The retinal vein occlusion market is slated to clock a favorable CAGR of 7.3% during the forecast period. In order to properly diagnose BRVO, there is a need for specialized tests such as fluorescein angiography, ocular coherence tomography (OCT), and color fundus photography. Apart from preventive care, clinicians are relying on laser therapy to help manage the symptoms of branch retinal vein occlusion.
It has been found that laser coagulation could effectively improve visual prognosis in patients with BRVO during three years of follow-up. Such trends are contributing to the growth of the global retinal vein occlusion market. It has been found that multiple laser treatments are required to achieve the desired results in patients. VitreoRetinal Surgery, PLLC - a provider of advanced retinal care in Minessota, is gaining recognition for offering laser treatment to BRVO patients.
Companies in the retinal vein occlusion market are increasing their output capacities in corticosteroid drugs that help to combat the inflammatory components, which lead to edema. On the other hand, healthcare professionals are acquiring proficiency in the focal laser therapy. This treatment provides lasers to areas of swelling to cause a reduction in edema.
Stakeholders in the retinal vein occlusion market are increasing their research in the pan-retinal photocoagulation therapy. This treatment is used when patients have new blood vessel formation following the retinal vein occlusion. On the other hand, anti-vascular endothelial growth factor (anti-VEGF) medications such as Lucentis, Avastin, and Eylea are being used in cases of BRVO where neovascularization or macular edema is present. These medications are directly injected in the eye and help inhibit abnormal blood vessels from growing.
One of the serious problems in BRVO is that of retinal neovascularization. In advanced cases, abnormal blood vessels grow from the retina into the vitreous gel of the eye. Since these vessels are very fragile, this can lead to major bleeding, also known as vitreous hemorrhage, and scar tissue formation. Hence, healthcare providers in the retinal vein occlusion market are increasing the availability of the laser photocoagulation treatment to the peripheral retina, which is found to be very helpful in this situation.
Laser treatment usually results in stabilization or even regression of the blood vessel growth. The bleeding caused due to retinal neovascularization may sometimes clear on its own but in a few cases will require the need for operation to remove the blood and the vitreous gel.
Expanding operations in future? To get the perfect launch ask for a custom report
Analysts’ Viewpoint
Telehealth services and mobile apps are encouraging individuals to seek professional treatment in cases where the severity of RVO is high amid the ongoing COVID-19 outbreak. OCT, ophthalmoscopy, and fluorescein angiography are helping in effective diagnosis of RVO. However, there is still a need for taking into consideration the medical history of patients while evaluating the treatment options for central retinal vein occlusion. Hence, stakeholders in the retinal vein occlusion market should work closely with medical practitioners to gain awareness about any risk factors that raise suspicion for a vein occlusion. Such efforts will help improve therapeutics and better patient outcomes.
Retinal Vein Occlusion Market: Key Segments
Retinal Vein Occlusion Market: Regional Outlook
Retinal Vein Occlusion Market Players
Retinal Vein Occlusion Market Snapshot
|
Attribute |
Detail |
|
Market Size Value in 2020 (Base Year) |
US$ 15.6 Bn |
|
Market Forecast Value in 2031 |
US$ 32.5 Bn |
|
Growth Rate (CAGR) |
7.3% |
|
Forecast Period |
2021–2031 |
|
Quantitative Units |
US$ Mn for Value |
|
Market Analysis |
It includes cross segment analysis at global as well as regional level. Furthermore, qualitative analysis includes drivers, restraints, opportunities, key industry events, etc. |
|
Competition Landscape |
|
|
|
|
Format |
Electronic (PDF) + Excel |
|
Market Segmentation |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Regions Covered |
|
|
|
|
|
|
|
|
|
|
Countries Covered |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Companies Profiled |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
Customization Scope |
Available upon request |
|
Pricing |
Available upon request |
Retinal Vein Occlusion Market – Segmentation
| Type |
|
| Treatment Type |
|
| Region |
|
The global retinal vein occlusion market was worth US$ 15.6 Bn and is projected to reach a value of US$ 32.5 Bn by the end of 2031
Retinal vein occlusion market is anticipated to grow at a CAGR of 7.3% during the forecast period
North America accounted for a major share of the global retinal vein occlusion market
Retinal vein occlusion market is driven by increase in the geriatric population, surge in awareness about eye disorders, improved healthcare infrastructure, technological advancements, and upcoming novel treatments
Key players in the global retinal vein occlusion market include Alimera Sciences, Allergan (AbbVie, Inc.), Annexin Pharmaceuticals AB (publ), Bayer AG, Carl Zeiss AG, F. Hoffmann-La Roche Ltd., Iridex Corporation, Lumenis, Nidek Co., Ltd., Novartis AG, Regeneron Pharmaceuticals, Inc., and Topcon Corporation
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Retinal Vein Occlusion Market
4. Market Overview
4.1. Introduction
4.1.1. Type Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Retinal Vein Occlusion Market Analysis and Forecast, 2017–2031
4.4.1. Market Revenue Projections (US$ Mn)
5. Key Insights
5.1. Key Industry Events
5.2. COVID-19 Pandemic Impact on Industry (value chain and short-/ mid-/ long-term impact)
6. Global Retinal Vein Occlusion Market Analysis and Forecast, by Type
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast by Type, 2017–2031
6.3.1. Central Retinal Vein Occlusion
6.3.2. Branch Retinal Vein Occlusion
6.4. Market Attractiveness Analysis, by Type
7. Global Retinal Vein Occlusion Market Analysis and Forecast, by Treatment Type
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by Treatment Type, 2017–2031
7.3.1. Anti-VEGF Drugs
7.3.2. Corticosteroid Drugs
7.3.3. Pan-retinal Photocoagulation Therapy
7.3.4. Laser Therapy
7.4. Market Attractiveness Analysis, by Treatment Type
8. Global Retinal Vein Occlusion Market Analysis and Forecast, by Region
8.1. Key Findings
8.2. Market Value Forecast, by Region
8.2.1. North America
8.2.2. Europe
8.2.3. Asia
8.2.4. Latin America
8.2.5. Middle East & Africa
8.3. Market Attractiveness Analysis, by Country/Sub-region/Region
9. North America Retinal Vein Occlusion Market Analysis and Forecast
9.1. Introduction
9.1.1. Key Findings
9.2. Market Value Forecast, by Type, 2017–2031
9.2.1. Central Retinal Vein Occlusion
9.2.2. Branch Retinal Vein Occlusion
9.3. Market Value Forecast, by Treatment Type, 2017–2031
9.3.1. Anti-VEGF Drugs
9.3.2. Corticosteroid Drugs
9.3.3. Pan-retinal Photocoagulation Therapy
9.3.4. Laser Therapy
9.4. Market Value Forecast, by Country, 2017–2031
9.4.1. U.S.
9.4.2. Canada
9.5. Market Attractiveness Analysis
9.5.1. By Type
9.5.2. By Treatment Type
9.5.3. By Country
10. Europe Retinal Vein Occlusion Market Analysis and Forecast
10.1. Introduction
10.1.1. Key Findings
10.2. Market Value Forecast, by Type, 2017–2031
10.2.1. Central Retinal Vein Occlusion
10.2.2. Branch Retinal Vein Occlusion
10.3. Market Value Forecast, by Treatment Type, 2017–2031
10.3.1. Anti-VEGF Drugs
10.3.2. Corticosteroid Drugs
10.3.3. Pan-retinal Photocoagulation Therapy
10.3.4. Laser Therapy
10.4. Market Value Forecast, by Country/Sub-region, 2017–2031
10.4.1. Germany
10.4.2. U.K.
10.4.3. France
10.4.4. Spain
10.4.5. Italy
10.4.6. Rest of Europe
10.5. Market Attractiveness Analysis
10.5.1. By Type
10.5.2. By Treatment Type
10.5.3. By Country/Sub-region
11. Asia Retinal Vein Occlusion Market Analysis and Forecast
11.1. Introduction
11.1.1. Key Findings
11.2. Market Value Forecast, by Type, 2017–2031
11.2.1. Central Retinal Vein Occlusion
11.2.2. Branch Retinal Vein Occlusion
11.3. Market Value Forecast, by Treatment Type, 2017–2031
11.3.1. Anti-VEGF Drugs
11.3.2. Corticosteroid Drugs
11.3.3. Pan-retinal Photocoagulation Therapy
11.3.4. Laser Therapy
11.4. Market Value Forecast, by Country/Sub-region, 2017–2031
11.4.1. China
11.4.2. Japan
11.4.3. India
11.4.4. Australia & New Zealand
11.4.5. Rest of Asia
11.5. Market Attractiveness Analysis
11.5.1. By Type
11.5.2. By Treatment Type
11.5.3. By Country/Sub-region
12. Latin America Retinal Vein Occlusion Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Type, 2017–2031
12.2.1. Central Retinal Vein Occlusion
12.2.2. Branch Retinal Vein Occlusion
12.3. Market Value Forecast, by Treatment Type, 2017–2031
12.3.1. Anti-VEGF Drugs
12.3.2. Corticosteroid Drugs
12.3.3. Pan-retinal Photocoagulation Therapy
12.3.4. Laser Therapy
12.4. Market Value Forecast, by Country/Sub-region, 2017–2031
12.4.1. Brazil
12.4.2. Mexico
12.4.3. Rest of Latin America
12.5. Market Attractiveness Analysis
12.5.1. By Type
12.5.2. By Treatment Type
12.5.3. By Country/Sub-region
13. Middle East & Africa Retinal Vein Occlusion Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Type, 2017–2031
13.2.1. Central Retinal Vein Occlusion
13.2.2. Branch Retinal Vein Occlusion
13.3. Market Value Forecast, by Treatment Type, 2017–2031
13.3.1. Anti-VEGF Drugs
13.3.2. Corticosteroid Drugs
13.3.3. Pan-retinal Photocoagulation Therapy
13.3.4. Laser Therapy
13.4. Market Value Forecast, by Country/Sub-region, 2017–2031
13.4.1. GCC Countries
13.4.2. South Africa
13.4.3. Rest of Middle East & Africa
13.5. Market Attractiveness Analysis
13.5.1. By Type
13.5.2. By Treatment Type
13.5.3. By Country/Sub-region
14. Competition Landscape
14.1. Market Player - Competition Matrix (by tier and size of companies)
14.2. Market Share Analysis, by Company, 2020
14.3. Company Profiles
14.3.1. Alimera Sciences
14.3.1.1. Company Description
14.3.1.2. Business Overview
14.3.1.3. Financial Overview
14.3.1.4. Strategic Overview
14.3.1.5. SWOT Analysis
14.3.2. Allergan (AbbVie, Inc.)
14.3.2.1. Company Description
14.3.2.2. Business Overview
14.3.2.3. Financial Overview
14.3.2.4. Strategic Overview
14.3.2.5. SWOT Analysis
14.3.3. Annexin Pharmaceuticals AB (publ)
14.3.3.1. Company Description
14.3.3.2. Business Overview
14.3.3.3. Strategic Overview
14.3.3.4. SWOT Analysis
14.3.4. Bayer AG
14.3.4.1. Company Description
14.3.4.2. Business Overview
14.3.4.3. Financial Overview
14.3.4.4. Strategic Overview
14.3.4.5. SWOT Analysis
14.3.5. Carl Zeiss AG
14.3.5.1. Company Description
14.3.5.2. Business Overview
14.3.5.3. Financial Overview
14.3.5.4. SWOT Analysis
14.3.6. F. Hoffmann-La Roche Ltd.
14.3.6.1. Company Description
14.3.6.2. Business Overview
14.3.6.3. Financial Overview
14.3.6.4. Strategic Overview
14.3.6.5. SWOT Analysis
14.3.7. Iridex Corporation
14.3.7.1. Company Description
14.3.7.2. Business Overview
14.3.7.3. Financial Overview
14.3.7.4. Strategic Overview
14.3.7.5. SWOT Analysis
14.3.8. Lumenis
14.3.8.1. Company Description
14.3.8.2. Business Overview
14.3.8.3. Strategic Overview
14.3.8.4. SWOT Analysis
14.3.9. Nidek Co., Ltd.
14.3.9.1. Company Description
14.3.9.2. Business Overview
14.3.9.3. Strategic Overview
14.3.9.4. SWOT Analysis
14.3.10. Novartis AG
14.3.10.1. Company Description
14.3.10.2. Business Overview
14.3.10.3. Financial Overview
14.3.10.4. Strategic Overview
14.3.10.5. SWOT Analysis
14.3.11. Regeneron Pharmaceuticals, Inc.
14.3.11.1. Company Description
14.3.11.2. Business Overview
14.3.11.3. Financial Overview
14.3.11.4. Strategic Overview
14.3.11.5. SWOT Analysis
14.3.12. Topcon Corporation
14.3.12.1. Company Description
14.3.12.2. Business Overview
14.3.12.3. Financial Overview
14.3.12.4. Strategic Overview
14.3.12.5. SWOT Analysis
List of Tables
Table 01: Global Retinal Vein Occlusion Market Value (US$ Mn) Forecast, by Type, 2017–2031
Table 02: Global Retinal Vein Occlusion Market Value (US$ Mn) Forecast, by Treatment Type, 2017-2031
Table 03: Global Retinal Vein Occlusion Market Value (US$ Mn) Forecast, by Region, 2017–2031
Table 04: North America Retinal Vein Occlusion Market Value (US$ Mn) Forecast, by Country, 2017–2031
Table 05: North America Retinal Vein Occlusion Market Value (US$ Mn) Forecast, by Type, 2017–2031
Table 06: North America Retinal Vein Occlusion Market Value (US$ Mn) Forecast, by Treatment Type, 2017-2031
Table 07: Europe Retinal Vein Occlusion Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 08: Europe Retinal Vein Occlusion Market Value (US$ Mn) Forecast, by Type, 2017–2031
Table 09: Europe Retinal Vein Occlusion Market Value (US$ Mn) Forecast, by Treatment Type, 2017-2031
Table 10: Asia Pacific Retinal Vein Occlusion Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 11: Asia Pacific Retinal Vein Occlusion Market Value (US$ Mn) Forecast, by Type, 2017–2031
Table 12: Asia Pacific Retinal Vein Occlusion Market Value (US$ Mn) Forecast, by Treatment Type, 2017-2031
Table 13: Latin America Retinal Vein Occlusion Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 14: Latin America Retinal Vein Occlusion Market Value (US$ Mn) Forecast, by Type, 2017–2031
Table 15: Latin America Retinal Vein Occlusion Market Value (US$ Mn) Forecast, by Treatment Type, 2017-2031
Table 16: Middle East & Africa Retinal Vein Occlusion Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 17: Middle East & Africa Retinal Vein Occlusion Market Value (US$ Mn) Forecast, by Type, 2017–2031
Table 18: Middle East & Africa Retinal Vein Occlusion Market Value (US$ Mn) Forecast, by Treatment Type, 2017-2031
List of Figures
Figure 01: Global Retinal Vein Occlusion Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031
Figure 02: Global Retinal Vein Occlusion Market Value Share (%), by Region, 2020
Figure 03: Global Retinal Vein Occlusion Market Value Share (%), by Type, 2020
Figure 04: Global Retinal Vein Occlusion Market Value Share (%), by Treatment Type, 2020
Figure 05: Confirmed Cases in Different Regions
Figure 06: Cumulative Total Confirmed & Death Cases in Top Countries
Figure 07: Global Retinal Vein Occlusion Market Value Share Analysis, by Type, 2020 and 2031
Figure 08: Global Retinal Vein Occlusion Market attractiveness index Analysis, by Type, 2021–2031
Figure 09: Global Retinal Vein Occlusion Market Revenue (US$ Mn), by Central Retinal Vein Occlusion, 2017–2031
Figure 10: Global Retinal Vein Occlusion Market Revenue (US$ Mn), by Branch Retinal Vein Occlusion, 2017–2031
Figure 11: Global Retinal Vein Occlusion Market Value Share Analysis, by Treatment Type, 2020 and 2031
Figure 12: Global Retinal Vein Occlusion Market Attractiveness Analysis, by Treatment Type, 2021–2031
Figure 13: Global Retinal Vein Occlusion Market Value (US$ Mn), Anti-VEGF Drugs, 2017–2031
Figure 14: Global Retinal Vein Occlusion Market Value (US$ Mn), Corticosteroid Drugs, 2017–2031
Figure 15: Global Retinal Vein Occlusion Market Value (US$ Mn), Pan-retinal Photocoagulation Therapy, 2017–2031
Figure 16: Global Retinal Vein Occlusion Market Value (US$ Mn), Laser Therapy, 2017–2031
Figure 17: Global Retinal Vein Occlusion Market Value Share Analysis, by Region, 2021 and 2031
Figure 18: Global Retinal Vein Occlusion Market Attractiveness Analysis, by Region, 2021–2031
Figure 19: North America Retinal Vein Occlusion Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031
Figure 20: North America Retinal Vein Occlusion Market Value Share Analysis, by Country, 2020 and 2031
Figure 21: North America Retinal Vein Occlusion Market Attractiveness Analysis, by Country, 2021–2031
Figure 22: North America Retinal Vein Occlusion Market Value Share Analysis, by Type, 2020 and 2031
Figure 23: North America Retinal Vein Occlusion Market Attractiveness Index Analysis, by Type, 2021–2031
Figure 24: North America Retinal Vein Occlusion Market Value Share Analysis, by Treatment Type, 2020 and 2031
Figure 25: North America Retinal Vein Occlusion Market Attractiveness Analysis, by Treatment Type, 2021–2031
Figure 26: Europe Retinal Vein Occlusion Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031
Figure 27: Europe Retinal Vein Occlusion Market Value Share Analysis, by Country/Sub-region, 2020 and 2031
Figure 28: Europe Retinal Vein Occlusion Market Attractiveness Analysis, by Country/Sub-region, 2021–2031
Figure 29: Europe Retinal Vein Occlusion Market Value Share Analysis, by Type, 2020 and 2031
Figure 30: Europe Retinal Vein Occlusion Market Attractiveness Index Analysis, by Type, 2021–2031
Figure 31: Europe Retinal Vein Occlusion Market Value Share Analysis, by Treatment Type, 2020 and 2031
Figure 32: Europe Retinal Vein Occlusion Market Attractiveness Analysis, by Treatment Type, 2021–2031
Figure 33: Asia Pacific Retinal Vein Occlusion Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031
Figure 34: Asia Pacific Retinal Vein Occlusion Market Value Share Analysis, by Country/Sub-region, 2020 and 2031
Figure 35: Asia Pacific Retinal Vein Occlusion Market Attractiveness Analysis, by Country/Sub-region, 2021–2031
Figure 36: Asia Pacific Retinal Vein Occlusion Market Value Share Analysis, by Type, 2020 and 2031
Figure 37: Asia Pacific Retinal Vein Occlusion Market Attractiveness Analysis, by Type, 2021–2031
Figure 38: Asia Pacific Retinal Vein Occlusion Market Value Share Analysis, by Treatment Type, 2020 and 2031
Figure 39: Asia Pacific Retinal Vein Occlusion Market Attractiveness Analysis, by Treatment Type, 2021–2031
Figure 40: Latin America Retinal Vein Occlusion Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031
Figure 41: Latin America Retinal Vein Occlusion Market Value Share Analysis, by Country/Sub-region, 2020 and 2031
Figure 42: Latin America Retinal Vein Occlusion Market Attractiveness Analysis, by Country/Sub-region, 2021–2031
Figure 43: Latin America Retinal Vein Occlusion Market Value Share Analysis, by Type, 2020 and 2031
Figure 44: Latin America Retinal Vein Occlusion Market Attractiveness Analysis, by Type, 2021–2031
Figure 45: Latin America Retinal Vein Occlusion Market Value Share Analysis, by Treatment Type, 2020 and 2031
Figure 46: Latin America Retinal Vein Occlusion Market Attractiveness Analysis, by Treatment Type, 2021–2031
Figure 47: Middle East & Africa Retinal Vein Occlusion Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031
Figure 48: Middle East & Africa Retinal Vein Occlusion Market Value Share Analysis, by Country/Sub-region, 2020 and 2031
Figure 49: Middle East & Africa Retinal Vein Occlusion Market Attractiveness Analysis, by Country/Sub-region, 2021–2031
Figure 50: Middle East & Africa Retinal Vein Occlusion Market Value Share Analysis, by Type, 2020 and 2031
Figure 51: Middle East & Africa Retinal Vein Occlusion Market Attractiveness Analysis, by Type, 2021–2031
Figure 52: Middle East & Africa Retinal Vein Occlusion Market Value Share Analysis, by Treatment Type, 2020 and 2031
Figure 53: Middle East & Africa Retinal Vein Occlusion Market Attractiveness Analysis, by Treatment Type, 2021–2031
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
Retinal Vein Occlusion Market Insights, 2021-2031
*86 figures and 60 tables includes